ÃÑ 4558ÆäÀÌÁö

4555ÆäÀÌÁö º»¹®½ÃÀÛ

¥´ ¿ë¿ª¿¬±¸ ¿¬±¸º¸°í¼­
¶ó. Á¤Ã¥È°¿ë
¸¶. Ÿ¿¬±¸/Â÷±â¿¬±¸¿¡ È°¿ë
¹Ù. ¾ð·ÐÈ«º¸ ¹× ´ë±¹¹Î±³À°
ÀÚü¿¬±¸
»ç. ±âŸ
º¸°í¼­
¿ªÇÐÁ¶»ç°ú
5.2 È°¿ë°èȹ
°¡) ¿¬±¸°á°ú¹°ÀÇ È°¿ë
Áúº´Áø´Ü°ú
1) »õ·Ó°Ô µµÃâµÈ PharmacophoreÀ» ÀÌ¿ëÇÏ¿© °¡»óŽ»öÀ» ÅëÇØ ÇÁ¸®¿Â º¯¼ºÀ» ÀúÇØÇÏ´Â »õ
µ¿¹°º¸È£°ú
·Î¿î hit µµÃâ °¡´É
2) µµÃâµÈ hitÀ» ÅëÇØ ¾ò¾îÁø °áÇÕ±¸Á¶¸¦ ¹ÙÅÁÀ¸·Î ±¸Á¶-È°¼º »çÀÌ »ó°ü°ü°è (SAR) ±Ô¸íÀ»
µ¿¹°¾àÇ°
°ü¸®°ú
ÅëÇØ À¯È¿¹°ÁúÀÇ ÃÖÀûÈ­ ¹× ÀúÇØÁ¦ °³¹ß ½Ã½ºÅÛÀ» È®¸³ ÇÒ ¼ö ÀÖÀ½.
µ¿¹°¾àÇ°
Æò°¡°ú
½Ä¹°°Ë¿ª
±â¼ú°³¹ß
Á¦6Àå ±âŸ Á߿亯°æ»çÇ×
¼¾ÅÍ
¿¬±¸±âȹ°ú
¼¼±ÕÁúº´°ú
Á¦7Àå Âü°í¹®Çå
±¸Á¦¿ª
Áø´Ü°ú
1. Prusiner, S.B., Prions. Proc Natl Acad Sci U S A, 1998. 95(23): p. 13363-83.
¹ÙÀÌ·¯½º
Áúº´°ú
2. Zahn, R., et al., NMR solution structure of the human prion protein. Proc Natl Acad
Sci U S A, 2000. 97(1): p. 145-50.
Á¶·ùÁúº´°ú
3. Baral, P.K., et al., Structural basis of prion inhibition by phenothiazine compounds.
ÇØ¿Ü
Structure, 2014. 22(2): p. 291-303.
Àü¿°º´°ú
4. Hyeon, J.W., et al., Discovery of Novel Anti-prion Compounds Using In Silico and
¼­¿ïÁö¿ª
º»ºÎ
In Vitro Approaches. Sci Rep, 2015. 5: p. 14944.
¿ë¿ª¿¬±¸
5. Kuwata, K., et al., Hot spots in prion protein for pathogenic conversion. Proc Natl
º¸°í¼­
Acad Sci U S A, 2007. 104(29): p. 11921-6.
6. Kamatari, Y.O., et al., Characterizing antiprion compounds based on their binding
properties to prion proteins: implications as medical chaperones. Protein Sci, 2013.
22(1): p. 22-34.
7. van der Kamp, M.W. and V. Daggett, Influence of pH on the human prion protein:
insights into the early steps of misfolding. Biophys J, 2010. 99(7): p. 2289-98.
4555
www.qia.go.kr

4555ÆäÀÌÁö º»¹®³¡



ÇöÀç Æ÷Ä¿½ºÀÇ ¾Æ·¡³»¿ëµéÀº µ¿ÀÏÇÑ ÄÁÅÙÃ÷¸¦ °¡Áö°í ÆäÀÌÁö³Ñ±è È¿°ú¹× ½Ã°¢Àû È¿°ú¸¦ Á¦°øÇÏ´Â ÆäÀÌÁöÀ̹ǷΠ½ºÅ©¸°¸®´õ »ç¿ëÀÚ´Â ¿©±â±îÁö¸¸ ³¶µ¶ÇϽðí À§ÀÇ ÆäÀÌÁöÀ̵¿ ¸µÅ©¸¦ »ç¿ëÇÏ¿© ´ÙÀ½ÆäÀÌÁö·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
»ó´Ü¸Þ´º ¹Ù·Î°¡±â ´ÜÃàÅ°¾È³» : ÀÌÀüÆäÀÌÁö´Â ÁÂÃø¹æÇâÅ°, ´ÙÀ½ÆäÀÌÁö´Â ¿ìÃø¹æÇâÅ°, ùÆäÀÌÁö´Â »ó´Ü¹æÇâÅ°, ¸¶Áö¸·ÆäÀÌÁö´Â ÇϴܹæÇâÅ°, ÁÂÃøÈ®´ëÃà¼Ò´Â insertÅ°, ¿ìÃøÈ®´ëÃà¼Ò´Â deleteÅ°